Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | CHRNA7 | P36544 | 5/20 | 0.57 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.54 |
| ▸ | HTR3B | O95264 | 1/20 | 0.54 |
| ▸ | HTR3A | P46098 | 1/20 | 0.54 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.54 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.54 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.53 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | SCN1A | P35498 | 1/20 | 0.51 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.51 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.51 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.50 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6399730 | 0.90 | MEN1 (0.56) | MEN1KMT2ACHRNA7HTR3EHTR3B | |
| SCHEMBL4145034 | 0.90 | CHRNA7 (0.54) | MEN1KMT2ACHRNA7HTR3EHTR3B | |
| SCHEMBL6399642 | 0.88 | KMT2A (0.55) | MEN1KMT2ACHRNA7HTR3EHTR3B | |
| SCHEMBL1786140 | 0.87 | MEN1 (0.69) | MEN1KMT2ACHRNA7HTR3EHTR3B | |
| SCHEMBL4453290 | 0.87 | MEN1 (0.69) | MEN1KMT2ACHRNA7HTR3EHTR3B | |
| SCHEMBL22105295 | 0.84 | MEN1 (0.58) | MEN1KMT2ACHRNA7HTR3EHTR3B | |
| SCHEMBL7413532 | 0.84 | PTPN2 (0.63) | MEN1KMT2ASCN1ASCN2ASCN3A | |
| SCHEMBL1926317 | 0.83 | MEN1 (0.65) | MEN1KMT2ACHRNA7HTR3EHTR3B | |
| SCHEMBL9248196 | 0.83 | MEN1 (0.65) | MEN1KMT2ACHRNA7HTR3EHTR3B | |
| SCHEMBL7407145 | 0.83 | PTPN2 (0.61) | MEN1KMT2ASCN1ASCN2ASCN3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 191 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260078106-A1 | Substituted Piperidino Compounds and Related Methods of Treatment | ALKERMES INC (US) | 2026-03-19 | — | — | US | disclosed |
| US-12441710-B2 | Substituted piperidino compounds and related methods of treatment | ALKERMES, INC. (US) | 2025-10-14 | — | — | US | disclosed |
| EP-4543446-A1 | SUBSTITUTED FUSED BICYCLIC COMPOUNDS AND RELATED METHODS OF TREATMENT | Alkermes, Inc. (US) | 2025-04-30 | — | — | EP | disclosed |
| EP-4263506-B1 | SUBSTITUTED PIPERIDINO COMPOUNDS AND RELATED METHODS OF TREATMENT | ALKERMES INC (US) | 2025-02-05 | — | — | EP | disclosed |
| EP-3227270-B1 | HETEROCYCLIC DERIVATIVES AND USE THEREOF | C&C RES LAB (KR) | 2024-11-13 | — | — | EP | disclosed |
| EP-4423069-A1 | INHIBITORS OF HIF-2ALPHA AND METHODS OF USE THEREOF | Arcus Biosciences, Inc. (US) | 2024-09-04 | — | — | EP | disclosed |
| US-12071411-B2 | Inhibitors of HIF-2α and methods of use thereof | ARCUS BIOSCIENCES, INC. (US) | 2024-08-27 | — | — | US | disclosed |
| CN-118176183-A | HIF-2 alpha inhibitors and methods of use thereof | 艾库斯生物科学有限公司 | 2024-06-11 | — | — | CN | disclosed |
| US-20240076283-A1 | Substituted Piperidino Compounds and Related Methods of Treatment | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2024-03-07 | — | — | US | disclosed |
| US-20240067639-A1 | SMALL MOLECULES THAT TARGET THE RNA THAT CAUSES ALS | University of Florida Research Foundation, Incorporation (US) | 2024-02-29 | — | — | US | disclosed |
| US-4257952-A | PSYCHOTROPIC DRUGS, ANALGESICS, ANTIHISTAMINES | STERLING DRUG INC. (US) | 1981-03-24 | — | — | US | disclosed |
| US-4235909-A | DOPAMINE ANTAGONISTS, IN THE TREATMENT OF PARKINSON'S DISEASE | ELI LILLY AND COMPANY (US) | 1980-11-25 | — | — | US | disclosed |
| US-4230861-A | DOPAMINE ANTAGONISTS | ELI LILLY AND COMPANY (US) | 1980-10-28 | — | — | US | disclosed |
| EP-0013788-A1 | Octahydro-2H-pyrrolo(3,4-g)quinolines, process for their preparation and pharmaceutical compositions containing them | ELI LILLY AND COMPANY (US) | 1980-08-06 | — | — | EP | disclosed |
| EP-0013787-A1 | Octahydro pyrazolo (3,4-g)quinolines, process for their preparation and pharmaceutical compositions containing them | ELI LILLY AND COMPANY (US) | 1980-08-06 | — | — | EP | disclosed |
| US-4212815-A | REACTING A KETONE WITH AN N,N-DISUBSTITUTED AMINOSULFUR TRIFLUORIDE | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1980-07-15 | — | — | US | disclosed |
| US-4198415-A | Prolactin inhibiting octahydro pyrazolo[3,4-g]quinolines | ELI LILLY AND COMPANY (US) | 1980-04-15 | — | — | US | disclosed |
| US-4172834-A | ANALGESICS, ANTIHISTAMINES AND PSYCHOTROPIC AGENTS | STERLING DRUG INC. (US) | 1979-10-30 | — | — | US | disclosed |
| US-4062864-A | ANALGESIC, PSYCHOTROPIC, ANTIHISTAMINE | STERLING DRUG INC. (US) | 1977-12-13 | — | — | US | disclosed |
| US-3959309-A | ANALGESICS, PSYCHOTROPIC, ANTIHISTAMINE | STERLING DRUG INC. (US) | 1976-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260078106-A1 | Substituted Piperidino Compounds and Related Methods of Treatment | HCRTR1, HCRTR2, NPY1R | MEN1 3118/4885KMT2A 521/4885CHRNA7 251/4885 |
| US-20240067639-A1 | SMALL MOLECULES THAT TARGET THE RNA THAT CAUSES ALS | FUS, SNRPE, RRBP1 | MEN1 3753/4885KMT2A 2470/4885CHRNA7 3564/4885 |
| US-12441710-B2 | Substituted piperidino compounds and related methods of treatment | HCRTR1, HCRTR2, PNMT | MEN1 3161/4885KMT2A 107/4885CHRNA7 86/4885 |
| US-12071411-B2 | Inhibitors of HIF-2α and methods of use thereof | HIF1AN, HIF1A, EGLN2 | MEN1 4122/4885KMT2A 797/4885CHRNA7 4854/4885 |
| US-20240076283-A1 | Substituted Piperidino Compounds and Related Methods of Treatment | HCRTR1, HCRTR2, PNMT | MEN1 3161/4885KMT2A 107/4885CHRNA7 86/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.